Login to Your Account

Gentium's Defibrotide Brings Sales Record as Launch Looms

By Cormac Sheridan
Staff Writer

Wednesday, August 14, 2013

Buoyed by the European Medicines Agency's recent reversal of its earlier negative decision on Defitelio (defibrotide), Gentium SpA unveiled its best ever quarter for the product and set out its stall on growing the market, albeit within a narrower indication.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription